Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Novartis’s oxcarbazepine. This neurogenic drug is now approved for the treatment of primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, in adults and children over two years old.
Originally approved in Switzerland in August 1997, the drug has since received marketing approvals in France, the UK, the US, and other countries, including China, where it is listed in both the National Essential Drug List and the National Reimbursement Drug List. Easton’s generic version follows ApicHope’s, which was the first to pass the Generic Quality Consistency Evaluation (GQCE).- Flcube.com
